Related Experiment Videos
Somatostatin analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in
R W Jansen1, T L Peeters, J W Lenders
1Department of Geriatric Medicine.
The Journal of Clinical Endocrinology and Metabolism
|April 1, 1989
Summary
Octreotide effectively prevents postprandial hypotension in elderly individuals by inhibiting insulin release, suggesting a new treatment for this condition.
Area of Science:
- Gerontology
- Cardiovascular Physiology
- Endocrinology
Background:
- Postprandial hypotension, a drop in blood pressure after meals, affects elderly individuals.
- The exact mechanisms, possibly involving insulin or gut hormones, remain unclear.
Purpose of the Study:
- To investigate the efficacy of octreotide in managing postprandial hypotension in elderly normotensive and hypertensive subjects.
- To explore the roles of vasoactive intestinal polypeptide (VIP) and insulin in this phenomenon.
Main Methods:
- A placebo-controlled study involving elderly normotensive and hypertensive subjects.
- Administration of oral glucose with and without octreotide (SMS 201-995).
- Monitoring of blood pressure, plasma glucose, insulin, and VIP levels.
Main Results:
- Placebo administration led to significant blood pressure reduction in both hypertensive and normotensive elderly subjects.
- Octreotide administration prevented the postprandial drop in blood pressure.
- Octreotide significantly blunted postprandial insulin spikes without affecting plasma VIP or glucose levels.
Conclusions:
- Octreotide shows promise as a treatment for symptomatic postprandial hypotension in the elderly.
- Vasoactive intestinal polypeptide (VIP) does not appear to be a significant mediator of postprandial hypotension.